Chronic inflammation has long been known to play a key role in the development of insulin resistance and therefore type 2 diabetes. The researchers believe that the anti-inflammatory properties of CBD could treat this inflammation and therefore improve the body’s metabolism.
Researchers at the Hebrew University of Jerusalem, led by Dr. Raphael Mechoulam, who is known for discovering cannabidol (CBD), observed CBD receptors in other bodily tissues.
The findings suggest that the therapeutic effects of CBD, a non-psychoactive compound, could be modified to fit different receptors. Different illness such as diabetes, atherosclerosis and cardiovascular disease could therefore be treated.
A study was conducted on rats with infarcts (areas of dead tissue) due to a failure of blood supply. When pretreated with CBD, these infarcts were 30 per cent smaller.
Chronic inflammation has long been known to play a key role in the development of insulin resistance and therefore type 2 diabetes. The researchers believe that the anti-inflammatory properties of CBD could treat this inflammation and therefore improve the body’s metabolism.
In addition, the immune system, cell growth, sugar metabolism and heart function all also appear to prospectively benefit from CBDs anti-inflammatory properties.
ISA Scientific, an Israeli company, recently signed a worldwide collaboration and licensing deal to establish therapies containing CBD.
Diabetes is the term for a group of related metabolic disorders characterized by prolonged high blood glucose levels. Diabetes affects almost 400 million people worldwide, resulting in up to five million deaths per year–and its prevalence is rising. Substantial evidence indicates that cannabis may prevent and treat the disease.
Diabetes is associated with high levels of fasting insulin and insulin resistance, as well as low levels of high-density lipoprotein cholesterol (HDL-C). In 2013, the results of a five-year study into the effects of cannabis on fasting insulin and insulin resistance were published in the American Journal of Medicine. Of the 4,657 respondents, 2,554 had used cannabis in their lifetime (579 were current users and 1,975 were past users) and 2,103 had never used the drug.
The researchers found that current users of cannabis had 16% lower fasting insulin levels than respondents who had never used cannabis, as well as having 17% lower levels of insulin resistance and higher levels of HDL-C. Respondents who had used cannabis in their lifetime but were not current users showed similar but less pronounced associations, indicating that the protective effect of cannabis fades with time.
The researchers also ran analyses on the data that excluded individuals diagnosed with diabetes. Even after excluding diabetics, current cannabis users were found to exhibit reduced fasting insulin and insulin resistance levels, indicating that cannabis can help prevent the occurrence of diabetes as well as controlling symptoms in diagnosed cases.
Type 1 or type 2
Insulin resistance (IR) is a condition that causes cells to reject the normal mechanism of insulin, a hormone that is produced by the pancreas and is fundamental to the regulation of glucose metabolism. IR is associated with type 2 diabetes; in type 1 diabetes, the body is unable to produce insulin, while in type 2, insulin production is unaffected but the cells are unable to process it. When cells become insulin-resistant, they are unable to absorb the glucose needed to supply them with energy, and the unused glucose builds up in the bloodstream–leading to hyperglycemia.
So basically, if you have type 2 diabetes, you need to be using cbd oil. Unless, you are tired of living. Get your cbd oil today.
